Ai-Ling Tian
Papers
1
Total Citations
77
H-Index
1
About
Dr. Ai-Ling Tian is a pioneering cancer biologist whose work bridges autophagy, immunotherapy, and drug resistance. Her most-cited study, “IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms” (2021, 77 citations), reveals a groundbreaking strategy: blocking the IGF1 receptor not only enhances autophagy but also mobilizes immune responses to dramatically boost the efficacy of existing cancer drugs. This dual mechanism—simultaneously activating cellular self-digestion and immune surveillance—offers a novel therapeutic avenue for overcoming treatment resistance. Dr. Tian’s research is distinguished by its translational potential, directly addressing the challenge of drug-refractory tumors. Her high-content/high-throughput screening of 65,000 compounds, performed on a robotized fluorescence microscope, exemplifies her commitment to rigorous, large-scale discovery. By identifying IGF1R inhibition as a master switch for both autophagy and immunity, she has opened new possibilities for combination therapies. With growing citation impact and a focus on clinically actionable targets, Dr. Tian is emerging as a leading voice in the quest to turn autophagy from a basic biological process into a powerful weapon against cancer.
Research Focus
Key Achievements
Top Papers
- 1